U.N. panel seeks to de-link R&D costs from drug prices

In a report released Wednesday, a U.N. panel called for investment in mechanisms that de-link R&D costs from health technologies' prices, as well as for greater transparency in drug pricing. The panel also said stakeholders should test and implement innovative financing mechanisms and new models for rewarding public health R&D, such as transaction taxes.

The U.N. High-Level Panel on Innovation and Access to Medicines issued the report. U.N. Secretary-General Ban Ki-moon convened the panel in November 2015. ...